Lidocaïne Accord

Lidocaine, the active ingredient in Lidocaïne Accord, is a local anesthetic (amide type) presented as a sterile solution for epidural, intramuscular and intravenous use. It provides reversible loss of sensation for minor surgical procedures, labor analgesia and regional anesthesia. GNH USA supplies Lidocaïne Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaïne Accord is a local anesthetic used in various procedural and pain‑management pathways. - Minor surgical or diagnostic procedures: provides rapid, reversible loss of sensation in the targeted tissue. - Epidural analgesia during labor or surgery: delivers continuous pain relief while preserving motor function. - Intravenous regional anesthesia (Bier block): produces rapid, localized anesthesia for limb surgeries.

Lidocaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Transient burning or stinging at the injection site - Mild hypotension - Dizziness or light‑headedness - Nausea or vomiting

Serious or Rare Side Effects: - Allergic reactions including anaphylaxis - Cardiac arrhythmias or conduction disturbances - Methemoglobinemia - Central nervous system toxicity such as seizures

Careful assessment and monitoring are required when using Lidocaïne Accord. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: monitor patients with heart block, conduction disorders or severe cardiac disease. - Dosage limits: avoid exceeding recommended total dose for the selected route of administration. - Concurrent CNS depressants: use caution when combined with other agents that depress the central nervous system. - Pregnancy and lactation: evaluate risk‑benefit; data are limited. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - General anesthetics (e.g., propofol, volatile agents): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk with regional techniques. - Monoamine oxidase inhibitors (MAOIs): potential for prolonged anesthetic effect. - Calcium channel blockers: may potentiate hypotensive effects.